Form 4: Madrigal Pharmaceuticals CEO Sibold Earns 50,000 Shares Following Performance Milestone

Madrigal Pharmaceuticals' CEO, William John Sibold, earned 50,000 shares of common stock on February 27, 2025, after meeting performance conditions tied to restricted stock units.

Summary

• William John Sibold, the President and CEO of Madrigal Pharmaceuticals, earned 50,000 shares of common stock on February 27, 2025.
• This earning was triggered by the achievement of performance and service conditions associated with Performance Restricted Stock Units (PSUs).
• These PSUs were part of a one-time sign-on award granted on September 11, 2023, which was contingent on significant stock price appreciation over a five-year period.
• Although earned, the shares will be settled and delivered on September 8, 2027, marking the fourth anniversary of Sibold's employment commencement.
• The original PSU award allowed Sibold to potentially earn up to 300% of the target award, with an additional 100,000 shares possible upon further stock price appreciation.

Sentiment

Score: 7

Explanation: The document indicates positive performance by the CEO and alignment of interests with shareholders through performance-based compensation. The sentiment is moderately positive.

Positives

• The CEO's earning of shares suggests the achievement of performance targets, potentially indicating positive company performance.
• The structure of the PSU award incentivizes sustained stock price appreciation, aligning management's interests with shareholders.

Future Outlook

The document outlines future share delivery on September 8, 2027, contingent on continued employment. It also highlights the potential for further share earnings based on stock price performance.

Industry Context

Executive compensation packages often include performance-based equity awards to align management incentives with shareholder value. The specific terms of Madrigal's PSU award, focusing on stock price appreciation, are designed to reward long-term growth.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units as part of their executive compensation packages.
• The specific performance metrics and vesting schedules vary depending on the company's strategic goals and industry benchmarks.
• The potential for earning up to 300% of the target award is relatively generous, suggesting a strong emphasis on incentivizing significant stock price appreciation.

Stakeholder Impact

• Shareholders may view the CEO's earning of shares positively, as it suggests the achievement of performance targets and alignment of interests.
• Employees may be motivated by the potential for executive compensation to be tied to company performance.

Key Dates